Estradiol-intranasal: A review of its use in the management of menopause

Drugs

Volumn 61, Issue 15, 2001, Pages 2243-2262

  Dooley, Mukta ^a   Spencer, Caroline M ^a   Ormrod, Douglas ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Estradiol intranasal; Estrogens; Hormone replacement therapy; Menopause; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

ANGIOTENSINOGEN; ANTITHROMBIN III; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 7; COLLAGEN; D DIMER; DYDROGESTERONE; ESTRADIOL; ESTRONE; FIBRINOGEN; FOLLITROPIN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; CLIMACTERIUM; CLINICAL TRIAL; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FIRST PASS EFFECT; HUMAN; INCIDENCE; MENOPAUSAL SYNDROME; POSTMENOPAUSE; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0035692209     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161150-00012     Document Type: Review

References (54)

1. Hormone replacement therapy
2. Cardiovascular pharmacology of hormone replacement therapy
3. Diagnosis, prophylaxis, and treatment of osteoporosis
4. Guidelines for counseling postmenopausal women about preventive hormone therapy
5. Hormone replacement therapy: The perspectives for the 21st century
6. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
7. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study
8. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
9. Efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms: Randomised dose-response study
10. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
11. Current hormone replacement therapy: What are the shortcomings? Advances in delivery
12. A practical guide to prescribing hormone replacement therapy
13. Educating patients about the benefits and drawbacks of hormone replacement therapy
14. Intranasal estradiol administration to oophorectomized women
15. Intranasal administration of estradiol in combination with progesterone to oophorectomized women: A pilot study
16. Effects of intranasal 17 β-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women
17. Clinical equivalence of intranasal and oral 17-β-estradiol for postmenopausal symptoms
18. Cardiovascular disease in postmenopausal women
19. Hormone exposure and effects on follical-stimulating hormone (FSH) after nasal admonistration of estradiol in postmenopausal women
20. Comparison of intranasal and transdermal 17 β-estradiol on bone loss in post-menopausal women at 1 year
21. Pulsed estrogen therapy: Pharmacokinetics of intra-nasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations
22. Randomized comparison of intranasal and transdermal estradiol
23. Endometrial safety and tolerability of Aerodiol Rm (intranasal estradiol) for 1 year
24. Clinical evaluation, dose-finding and acceptability of AERODIOL, the pulsed estrogen therapy for treatment of climacteric symptoms
25. Hormone therapy to prevent disease and prolong life in postmenopausal women
26. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
27. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women
28. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
29. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy
30. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
31. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
32. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
33. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
34. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study
35. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
36. Prospective study of exogenous hormones and risk of pulmonary embolism in women
37. Risk of venous thromboembolism in users of hormone replacement therapy
38. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
39. Pharmacokinetic and pharmacologic variation between different estrogen products
40. Biological effects of estradiol-17β in postmenopausal women: Oral versus percutaneous administration
41. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate
42. Estradiol implants (Organon)
43. The role of androgen in the maintenance of sexual functioning in oophorectomized women
44. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms
45. Effect of SERMs on the uterus and menopausal symptoms
46. Selective estrogen receptor modulators and phytoestrogens: New therapies for the postmenopausal women
47. Clinical effects of raloxifene hydrochloride in women
48. Compliance with hormonal replacement therapy
49. The need to improve compliance to HRT